Loading...
Printed on 6/29/2026
For informational purposes only. This is not medical advice.
The New York Heart Association (NYHA) Functional Classification is the most commonly used system for describing the severity of heart failure symptoms. It classifies patients into four classes based on how much they are limited during physical activity: Class I (no limitation), Class II (slight limitation — symptoms with ordinary activity), Class III (marked limitation — symptoms with less than ordinary activity), and Class IV (unable to carry on any activity without discomfort — symptoms at rest). NYHA class is used in treatment guidelines, clinical trials, and prognostication.
Formula: Subjective classification based on physical activity tolerance. Classes I–IV.
Save your results with a free account
Keep a history of calculations, favorite tools, and access your dashboard anytime.
Ask the patient about symptoms (fatigue, dyspnea, palpitations, chest pain) during ordinary activities like walking, climbing stairs, carrying groceries, and at rest. Class I = no symptoms with ordinary activity; Class II = slight limitation, comfortable at rest but symptomatic with moderate exertion; Class III = marked limitation, comfortable at rest but symptomatic with less-than-ordinary exertion; Class IV = unable to carry on any activity without discomfort, symptoms present at rest.
Based on the patient's reported functional capacity, assign one of four classes. Class II includes symptoms walking up stairs or carrying light objects. Class III includes symptoms with activities of daily living such as dressing or slow walking. Class IV includes symptoms at rest and inability to perform any physical activity without distress.
Use the NYHA class to guide guideline-directed medical therapy (GDMT): ACE inhibitors/ARBs/ARNI + beta-blockers + MRA + SGLT2 inhibitors are indicated for NYHA II-IV with reduced EF. ICD and CRT device therapy is indicated for NYHA II-III with EF ≤35%. NYHA III-IV refractory to GDMT should be evaluated for LVAD or cardiac transplant.
Cardiologists, heart failure nurses, primary care physicians
NYHA classification provides a standardized, reproducible way to describe functional severity at each clinical visit, enabling tracking of disease trajectory and communicating status across care teams.
Cardiologists, internal medicine physicians
GDMT for HFrEF (ACE inhibitors/ARBs, sacubitril/valsartan, beta-blockers, spironolactone, SGLT2 inhibitors) is recommended for NYHA II-IV. NYHA class guides when to start, titrate, and combine these agents per ACC/AHA and ESC guidelines.
Electrophysiologists, heart failure specialists
ICD implantation is recommended for NYHA II-III with LVEF ≤35% on optimal GDMT. CRT (cardiac resynchronization therapy) is indicated for NYHA II-III with LVEF ≤35% and LBBB on ECG. NYHA class is a key eligibility criterion for these life-saving device therapies.
Advanced heart failure specialists, transplant cardiologists
NYHA III-IV refractory to GDMT — Stage D heart failure — should be referred for advanced therapies: left ventricular assist device (LVAD) as bridge-to-transplant or destination therapy, or cardiac transplant evaluation. NYHA class is required for transplant listing.
Clinicians, patients, palliative care teams
NYHA class correlates strongly with prognosis. NYHA IV carries approximately 50% annual mortality without advanced intervention. This information guides goals-of-care conversations, palliative care referrals, and shared decision-making about aggressive vs. comfort-focused management.
Researchers, clinical trialists
Major landmark HF trials (SOLVD, MERIT-HF, RALES, PARADIGM-HF) used NYHA class as an enrollment criterion and primary endpoint. NYHA II-III HFrEF is the core population for most current HF research and regulatory approvals.
NYHA Class IV represents end-stage heart failure with symptoms at rest. Annual mortality approaches 50% without advanced intervention (REMATCH trial). These patients warrant urgent evaluation for LVAD or transplant if eligible, or goals-of-care discussions if not.
All four pillars of GDMT for HFrEF — ACEi/ARB/ARNI, beta-blocker, MRA (spironolactone/eplerenone), and SGLT2 inhibitor (dapagliflozin/empagliflozin) — are indicated for NYHA II-IV HFrEF. Together they reduce mortality by ~55% relative to placebo. Starting and titrating these agents is the most impactful intervention in heart failure management.
NYHA class can improve significantly after optimizing GDMT over 3-6 months. A patient presenting as NYHA III may improve to NYHA II or even Class I with full-dose GDMT. Reassessment is essential because device therapy thresholds (EF ≤35%, NYHA II-III) should only be applied after 3+ months of optimized GDMT.
Inter-observer variability for NYHA is moderate (kappa 0.55-0.70 in studies). Supplement with the 6-minute walk test (6MWT) for objective functional assessment, BNP/NT-proBNP for congestion monitoring, and peak VO2 by cardiopulmonary exercise testing for transplant/LVAD evaluation.
Cardiac resynchronization therapy (CRT) provides the greatest mortality benefit in patients with NYHA II-III HFrEF, LVEF ≤35%, and left bundle branch block (LBBB) with QRS ≥150 ms. CRT in NYHA IV is generally contraindicated except as bridge to transplant, as outcomes are poor.
Current ACC/AHA and ESC guidelines are less definitive about device therapy indications for HFpEF (EF ≥50%). ICD and CRT indications were established in HFrEF trials. NYHA class still guides pharmacotherapy in HFpEF (SGLT2 inhibitors, diuretics), but device therapy decisions differ.
The ACC/AHA staging system (A=at risk, B=structural disease without symptoms, C=symptomatic HF, D=refractory) captures patients before symptoms develop. Stage A/B patients have NYHA Class I but still benefit from RAAS blockade if they have EF <40%. Use both systems together for comprehensive assessment.
Loop diuretics (furosemide, torsemide) are the cornerstone of decongestion and improve NYHA class and quality of life. However, diuretics do not reduce mortality — unlike GDMT agents. Achieving and maintaining euvolemia is essential before titrating GDMT, which does extend survival.
NT-proBNP >125 pg/mL or BNP >35 pg/mL in stable HF patients correlates with higher NYHA class and worse outcomes. NT-proBNP-guided therapy (titrating GDMT to reduce NT-proBNP) has shown outcome benefit in some trials (GUIDE-IT, PRIMA). Serial natriuretic peptide monitoring complements NYHA class reassessment.
NYHA class reflects what the patient reports, not necessarily HF severity. Severe obesity, COPD, deconditioning, orthopedic limitations, or severe anemia can all limit exercise capacity and inflate apparent NYHA class. Always assess whether symptoms are cardiac in etiology before assigning a high NYHA class and escalating HF therapy.
NYHA Classification from the New York Heart Association Criteria Committee (Little Brown and Co, 1964). Updated 1994 by ACC/AHA. NYHA class as endpoint in major HF trials: SOLVD (ACEi, NEJM 1991), MERIT-HF (metoprolol succinate, LANCET 1999), RALES (spironolactone, NEJM 1999), PARADIGM-HF (sacubitril/valsartan, NEJM 2014). NYHA IV 1-year mortality ~50% (REMATCH trial, Rose et al., NEJM 2001). Inter-rater variability: Goldman et al. (NEJM 1981). ACC/AHA Heart Failure Staging and 2022 Guideline Update (Heidenreich et al., JACC 2022). CRT and ICD indications: ACC/AHA/HRS Device Guidelines (Epstein et al., JACC 2013).
Your NYHA functional classification describes the degree to which heart failure symptoms limit your daily physical activity. Class I indicates no limitation — you can perform ordinary physical activity without undue fatigue, dyspnea, or palpitations. Class II indicates slight limitation — you are comfortable at rest, but ordinary physical activities such as walking up stairs or carrying groceries cause symptoms. Class III indicates marked limitation — you are comfortable only at rest, and even less-than-ordinary activity (such as getting dressed or walking short distances on flat ground) produces symptoms. Class IV indicates inability to carry out any physical activity without discomfort, with symptoms present even at rest.
Your NYHA class is dynamic and can change over time with treatment or disease progression. Improvement from a higher class (e.g., III to II) after initiating guideline-directed medical therapy is a positive sign indicating treatment response. Worsening class may signal decompensation requiring therapy adjustment.
Use the NYHA classification to describe and communicate the functional severity of heart failure at any point in the disease course. It is most commonly applied during initial heart failure diagnosis, at follow-up visits to track disease trajectory, and when making treatment decisions based on guideline recommendations. Major heart failure guidelines (ACC/AHA, ESC) reference NYHA class for therapy escalation — for example, aldosterone antagonists are recommended for Class II–IV patients, and advanced therapies like ICD, CRT, or LVAD are considered primarily for Class III–IV patients.
NYHA class is also essential for communication between clinicians, as it provides a standardized shorthand for functional status. It is used in clinical trial enrollment criteria, disability assessments, transplant candidacy evaluations, and prognostic discussions with patients and families.
The NYHA classification is inherently subjective — it depends on the patient's self-reported symptom burden and the clinician's interpretation. Two different clinicians may assign different NYHA classes to the same patient, and patients may under-report or over-report their limitations. There is no objective test or measurement that defines each class, which limits reproducibility.
The classification also does not capture the full complexity of heart failure. It reflects functional limitation at a single point in time and does not account for ejection fraction, cardiac biomarkers (BNP/NT-proBNP), echocardiographic parameters, or comorbidities that influence prognosis. A patient with NYHA Class II symptoms may have severe structural disease with a high risk of sudden death, while another Class II patient may have a much more favorable prognosis. For comprehensive risk assessment, NYHA class should be combined with objective measures such as the MAGGIC score, peak VO2 from cardiopulmonary exercise testing, or natriuretic peptide levels.
For related assessments, see CHA₂DS₂-VASc Score and Framingham Risk.
Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.
April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.
Calculate the CHA₂DS₂-VASc score to estimate stroke risk in patients with atrial fibrillation and guide anticoagulation therapy decisions.
OpenCardiologyCalculate 10-year cardiovascular disease risk with the Framingham Risk Score using age, cholesterol, blood pressure, smoking, and diabetes inputs.
Open